Worldwide, people are suffering from the consequences of Hepatitis B (HB) virus infection, such as liver cirrhosis and liver cell carcinoma. Currently available vaccines are protective in most of the vaccinated population. However, a small part of the population does not respond to these vaccines and they are called (non-responders). The innovative adjuvant AI20 has been developed by CyTuVax to improve the standardized Hepatitis B vaccine for the protection of non-responders.